Definium Therapeutics Valuation
| DFTX Stock | 16.90 0.65 4.00% |
At this time, the firm appears to be overvalued. Definium Therapeutics shows a prevailing Real Value of USD13.22 per share. The current price of the firm is USD16.9. Our model computes the value of Definium Therapeutics from reviewing the firm fundamentals such as Working Capital of 242.77 M, retained earnings of (398.88 M), and Total Debt of 21.85 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Definium Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Definium Therapeutics is based on 3 months time horizon. Increasing Definium Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Definium Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Definium Stock. However, Definium Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.9 | Real 13.22 | Hype 17.15 | Naive 15.63 |
The intrinsic value of Definium Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Definium Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Definium Therapeutics helps investors to forecast how Definium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Definium Therapeutics more accurately as focusing exclusively on Definium Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Definium Therapeutics' intrinsic value based on its ongoing forecasts of Definium Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Definium Therapeutics' closest peers.
Definium Therapeutics Cash |
|
Definium Valuation Drivers Correlation
Many accounts on the financial statements of Definium Therapeutics are highly interrelated and sometimes correlated. Consequently, when conducting Definium's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Definium
Click cells to compare fundamentals
About Definium Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Definium Therapeutics. We calculate exposure to Definium Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Definium Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -606 K | -636.4 K |
Definium Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Definium Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Definium we look at many different elements of the entity such as Definium's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Definium Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Definium Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Definium Therapeutics' worth.Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.